- Market Capitalization, $K 662,519
- Shares Outstanding, K 108,967
- Annual Sales, $ 0 K
- Annual Income, $ -97,910 K
- 60-Month Beta 0.87
- Price/Sales 254.28
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+0.14 (+2.36%)since 06/01/22
| || |
+1.73 (+39.77%)since 04/01/22
| || |
+3.50 (+135.66%)since 07/01/21
/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors...
A strong launch for the company's first commercialized drug drew a cheer from investors.
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can...
An increasing focus on integrating advanced technologies into research efforts to generate viable drugs for treating various critical ailments, and growing demand for therapies from an aging population,...
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.